Sentences with phrase «protein as a biomarker»
«This is, however, an important pre-requisite in order to detect proteins as biomarkers, i.e. as indicators of certain diseases, or new drug targets.»
https://www.sciencedaily.com/
Gross cystic disease fluid protein - 15 / prolactin - inducible protein as a biomarker for keratoconus disease.
Not exact matches
In particular, protein tyrosine phosphatase, receptor type, F (PTPRF) may serve as a biomarker linking insulin resistance with insufficient milk supply.
An analysis of the results identified four of the proteins as potential biomarkers.
The selected stationary phases fully leverage the separation power of sub-2-µm particle technology, delivering the efficiency and selectivity required for complex separations such as discovery of low - abundance species, peptide mapping, protein identification, and biomarker discovery.
Larger biomarker signatures can be detected with technology from CDI Laboratories, which offers microarrays of functional human proteins (over 20,000 on a single array) to test the antibodies present in human liquid biopsy samples, such as blood, serum, plasma, CSF, or tissue lysates.
Biomarker data management platforms become even more essential as different types of biomarkers are analyzed together, such as proteins and miRNAs.
About 15 to 20 % of breast cancers are classified as «triple negative,» so called because these tumors do not express three key proteins that are biomarkers and / or drug targets for breast cancer: the estrogen receptor, the progesterone receptor, and HER2 (a member of the epidermal growth factor receptor family).
«Starting with our cell model that mimics human pancreatic cancer progression, we identified released proteins, then tested and validated a subset of these proteins as potential plasma biomarkers of this cancer,» Zaret said.
The single molecule array (Simoa) technology developed by Quanterix, and the fully automated HD - 1 analyzer, offers unprecedented improvement in sensitivity proteins over current technologies for the detection of blood - based biomarkers — as much as 1000 times more sensitive than conventional immunoassays.
They begin as long, linear strands of DNA, but are decorated with proteins that bind to a matching protein biomarker of interest.
The larger scale Cancer Genome Atlas study provided the information needed to alter proteins or RNA sequences that may act as «drivers» for prognostic biomarkers or therapeutic targets.
Two other big initiatives fared better: a proteomics effort to identify proteins in blood and other biomarkers that might work as early warning signs of cancer, and the most recent: a human Cancer Genome Atlas.
Another limitation of the study was that researchers did not analyze a blood biomarker called C - Reactive Protein (CRP) as a measure of inflammation to select patients to be enrolled into the study.
The authors say these sets of proteins can serve as biomarkers for monitoring autophagy in the clinical setting.
Blood contains proteins, enzymes, lipids, metabolites, and peptides that serve as biomarkers for health screening, monitoring and diagnostics.
And, critically, the study showed that levels of two biomarkers, known as L - threonine (an amino acid) and vitamin D binding protein, may accurately predict which patients live and which die.
The scientists found that levels of two biomarkers, known as L - threonine (an amino acid) and vitamin - D - binding - protein, may accurately predict which patients live and which die.
They found that in all nine cases, their data matched the outcomes seen in patients, as measured by clinical protein biomarkers found in the bloodstream, which are used by doctors to determine whether a drug is killing the tumor cells.
They identified CXCL9 protein and CXCL9 mRNA as potential biomarkers — molecules that indicate the effect or progress of a disease — for the diagnosis of rejection.
New protein biomarkers would ideally show specific brain pathologies and act as early indicators of disease.
One promising avenue of research involves searching for biomarkers such as tau proteins in the cerebrospinal fluid of patients.
The researchers also are seeking other potential drug targets in the 50 percent of patients who don't have high levels of the anti-death protein, as well as biomarkers in addition to CA125 that could be used to screen for ovarian cancer.
Antibody microarrays are powerful tools for simultaneous detection of hundreds or thousands of blood - borne protein biomarkers at once, potentially allowing accurate fingerprinting and improved diagnostics of complex pathophysiological states such as cancers, neurodegenerative diseases and autoimmune conditions.
Specific proteins and chemicals in the samples are used as biomarkers, or indicators of health.
UNISI provides expertise in the measurement of cell signalling proteins, such as cytokines, chemokines and inflammatory biomarkers in multiple samples (including serum, plasma and tissue culture supernatants), using a multiplex suspension array system or a flow cytometric bead assay.
However, to enable sensitivity needed to detect low abundant protein biomarkers such as cytokines and tissue leakage proteins, -LSB-...]
FOCUS FOR BASIC AND CLINICAL RESEARCH Dr. De Vivo noted that there is a need to define outcome measures such as muscle strength and function; pulmonary function; quality of life; and surrogate biomarkers including blood cell SMN transcripts and protein.
Why it matters: Because the secretome is important for tissue function and equilibrium as well as cell communication, proliferation and organization, studying these proteins may lead to new treatments and biomarker discovery.
To cite a few instances, polymerase chain reaction (PCR), a molecular method developed over three decades ago, has been widely applied in disease diagnosis, disease mechanism deciphering, and prognosis prediction; the elucidation of tyrosine kinase activity in cancer cells has led to the development of novel drugs for cancer treatment; and the identification of proteins and genetic molecules by molecular methods as biomarkers for disease diagnosis and prognosis has been drawing great interest.
The Clinical Biomarkers Facility offers services for high - throughput and highly specific analyses of protein biomarker candidates in body fluids such as plasma, serum, cerebrospinal fluids etc. and cell and tissue lysates using molecular tools such as proximity extension and proximity ligation technologies (PEA and PLA) providing assays with high specificity and sensitivity in complex biological matrices.
Akassoglou also thinks fibrinogen and other blood clotting proteins could serve as a biomarker for MS.. A biomarker is a measurable indicator of the presence or severity of a disease, enabling physicians and researchers to track disease progression.
Camp and colleagues evaluated the correlation of TMAs to whole tissue sections and concluded that 2 separate cores allowed accurate assessment of protein expression, although this is clearly biomarker dependent, as heterogeneity varies from marker to marker [35].
Importantly, newly identified proteins will serve as disease biomarkers and will contribute to the development of novel therapeutic strategies.
Their work encompasses several strategies, including: developing FL - HCC animal models to characterize tumor - immune interactions, exploring if a mutated protein associated with FL - HCC could be targeted by immunotherapy, identifying immune checkpoints that could potentially serve as targets for immunotherapy as well as biomarkers for analyzing patients, and evaluating the effectiveness of immunotherapy strategies against FL - HCC patient samples in the lab.
Susan Amara, USA - «Regulation of transporter function and trafficking by amphetamines, Structure - function relationships in excitatory amino acid transporters (EAATs), Modulation of dopamine transporters (DAT) by GPCRs, Genetics and functional analyses of human trace amine receptors» Tom I. Bonner, USA (Past Core Member)- Genomics, G protein coupled receptors Michel Bouvier, Canada - Molecular Pharmacology of G protein - Coupled Receptors; Molecular mechanisms controlling the selectivity and efficacy of GPCR signalling Thomas Burris, USA - Nuclear Receptor Pharmacology and Drug Discovery William A. Catterall, USA (Past Core Member)- The Molecular Basis of Electrical Excitability Steven Charlton, UK - Molecular Pharmacology and Drug Discovery Moses Chao, USA - Mechanisms of Neurotophin Receptor Signaling Mark Coles, UK - Cellular differentiation, human embryonic stem cells, stromal cells, haematopoietic stem cells, organogenesis, lymphoid microenvironments, develomental immunology Steven L. Colletti, USA Graham L Collingridge, UK Philippe Delerive, France - Metabolic Research (diabetes, obesity, non-alcoholic fatty liver, cardio - vascular diseases, nuclear hormone receptor, GPCRs, kinases) Sir Colin T. Dollery, UK (Founder and Past Core Member) Richard M. Eglen, UK Stephen M. Foord, UK David Gloriam, Denmark - GPCRs, databases, computational drug design, orphan recetpors Gillian Gray, UK Debbie Hay, New Zealand - G protein - coupled receptors, peptide receptors, CGRP, Amylin, Adrenomedullin, Migraine, Diabetes / obesity Allyn C. Howlett, USA Franz Hofmann, Germany - Voltage dependent calcium channels and the positive inotropic effect of beta adrenergic stimulation; cardiovascular function of cGMP protein kinase Yu Huang, Hong Kong - Endothelial and Metabolic Dysfunction, and Novel Biomarkers in Diabetes, Hypertension, Dyslipidemia and Estrogen Deficiency, Endothelium - derived Contracting Factors in the Regulation of Vascular Tone, Adipose Tissue Regulation of Vascular Function in Obesity, Diabetes and Hypertension, Pharmacological Characterization of New Anti-diabetic and Anti-hypertensive Drugs, Hypotensive and antioxidant Actions of Biologically Active Components of Traditional Chinese Herbs and Natural Plants including Polypehnols and Ginsenosides Adriaan P. IJzerman, The Netherlands - G protein - coupled receptors; allosteric modulation; binding kinetics Michael F Jarvis, USA - Purines and Purinergic Receptors and Voltage-gated ion channel (sodium and calcium) pharmacology Pain mechanisms Research Reproducibility Bong - Kiun Kaang, Korea - G protein - coupled receptors; Glutamate receptors; Neuropsychiatric disorders Eamonn Kelly, Prof, UK - Molecular Pharmacology of G protein - coupled receptors, in particular opioid receptors, regulation of GPCRs by kinasis and arrestins Terry Kenakin, USA - Drug receptor pharmacodynamics, receptor theory Janos Kiss, Hungary - Neurodegenerative disorders, Alzheimer's disease Stefan Knapp, Germany - Rational design of highly selective inhibitors (so call chemical probes) targeting protein kinases as well as protein interaction inhibitors of the bromodomain family Andrew Knight, UK Chris Langmead, Australia - Drug discovery, GPCRs, neuroscience and analytical pharmacology Vincent Laudet, France (Past Core Member)- Evolution of the Nuclear Receptor / Ligand couple Margaret R. MacLean, UK - Serotonin, endothelin, estrogen, microRNAs and pulmonary hyperten Neil Marrion, UK - Calcium - activated potassium channels, neuronal excitability Fiona Marshall, UK - GPCR molecular pharmacology, structure and drug discovery Alistair Mathie, UK - Ion channel structure, function and regulation, pain and the nervous system Ian McGrath, UK - Adrenoceptors; autonomic transmission; vascular pharmacology Graeme Milligan, UK - Structure, function and regulation of G protein - coupled receptors Richard Neubig, USA (Past Core Member)- G protein signaling; academic drug discovery Stefan Offermanns, Germany - G protein - coupled receptors, vascular / metabolic signaling Richard Olsen, USA - Structure and function of GABA - A receptors; mode of action of GABAergic drugs including general anesthetics and ethanol Jean - Philippe Pin, France (Past Core Member)- GPCR - mGLuR - GABAB - structure function relationship - pharmacology - biophysics Helgi Schiöth, Sweden David Searls, USA - Bioinformatics Graeme Semple, USA - GPCR Medicinal Chemistry Patrick M. Sexton, Australia - G protein - coupled receptors Roland Staal, USA - Microglia and neuroinflammation in neuropathic pain and neurological disorders Bart Staels, France - Nuclear receptor signaling in metabolic and cardiovascular diseases Katerina Tiligada, Greece - Immunopharmacology, histamine, histamine receptors, hypersensitivity, drug allergy, inflammation Georg Terstappen, Germany - Drug discovery for neurodegenerative diseases with a focus on AD Mary Vore, USA - Activity and regulation of expression and function of the ATP - binding cassette (ABC) transporters
UNISI will provide expertise in the measurement of cell signalling proteins, such as cytokines, chemokines and inflammatory biomarkers in multiple samples (including serum, plasma and tissue culture supernatants), using a multiplex suspension array system or a Cytometric bead assay.
These spatial differences of protein expression include proteins that have previously been identified as HCC biomarkers.
In this study we report a number of proteins that could be validated as potential biomarkers of ECM.
With respect to biomarkers, we believe our proteomic strategy [10], that did not require prior knowledge of which proteins might be present in the CSF, will accelerate the transition from a discovery phase of candidate biomarkers, as described in this study, to full validation for clinical application.
We regard the proteins that were identified only in one group or differentially abundant between groups, as possible or candidate biomarkers that can be subjected to further analysis in validation and verification studies.
Women with elevated inflammatory biomarkers, such as elevated C - reactive protein also report poor sleep quality and depression.
Researchers followed a subset of 1,139 subjects and found that those with the greatest increases in urinary polyphenols had significantly lower levels of five different biomarkers of inflammation, such as adhesion molecules, interleukin, tumor necrosis factor alpha, and monocyte chemotactic protein.
See UTILITY OF AUTOANTIBODY BIOMARKERS FOR DETECTION OF ALZHEIMER»S DISEASE (Parkinson's was looked at as well) and Neuronal PAD4 expression and protein citrullination: possible role in production of autoantibodies associated with neurodegenerative disease.
They also measured an extensive array of biomarkers of both endothelial dysfunction (such as von Willebrand factor) and low - grade inflammation (including C - reactive protein and serum amyloid A).
Read about the use of cobalamin - specific proteins as potential biomarkers to help diagnose, stage and monitor treatment response which may be used to direct NO - Cbl therapy.
First, depression has been linked to multiple biological abnormalities, including vascular pathologic changes, autonomic function changes, hypercoagulability, and hypothalamic - pituitary - adrenal axis hyperactivity.10 Evidence shows that depression in adulthood is linked to elevated risk of developing cardiovascular disease, diabetes, and dementia in later life.11 Second, inflammation contributes to atherosclerosis, insulin resistance, and neurodegeneration.12 - 14 Evidence shows that elevation in inflammation biomarkers, such as C - reactive protein (CRP), in adulthood predicts the development of cardiovascular disease, diabetes, and dementia in later life.15 - 17 Third, metabolic abnormalities such as obesity, dyslipidemia, glucose intolerance, hypertension, and cardiorespiratory fitness contribute to vascular lesions and hormonal imbalance.